Press release from Companies
Publicerat: 2022-03-03 08:45:00
Cessatech A/S ("Cessatech" or the "Company") hereby publishes its annual report for the fiscal year 2021. The annual report including the auditor’s report is attached as a pdf. The report is also available on Cessatech’s website www.cessatech.com under ‘Fillings & Reports’
Full year 2021 (1 January – 31 December): *Earnings per share (DKK per share): Operating result divided by the average number of shares during the period. The total number of shares as of 31 December 2021 amounted to 6.112.535 shares, the average number of shares during the full year was 3,740,145 There has been an increase in the number of shares in Q4 related to the exercise of warrant TO 1. **Solidity: Total equity divided by total capital and liability. Highlights during the full year 2021 Q2-2021 For more information about Cessatech, please contact: About Cessatech
Q1-2021
Q3-2021
Q4-2021
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com
Cessatech A/S is a Danish pharmaceutical company committed to developing and commercialising evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, being easy to administer, a fast-acting therapeutic effect and being medically approved for children. CT001 is at its pivotal stage of clinical development.